Yangxinshi

ApprovedSmall molecule

SSPH Qingdao Growful Pharmacetical Co.,Ltd

Yangxinshi is one of 42 small molecule programs targeting Heart Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart DiseaseActive, not recruiting

Heart DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

166 competitors in Heart Disease

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

9 2

Biaxin

AbbVie

Phase 3

1 3

Aldactone

Pfizer

Phase 3

1 4

Ozempic

Novo Nordisk

Phase 3

1 5

Lopid

Pfizer

Phase 3

1 6

Depo-Provera

Activella

Zoloft

VViatris Specialty LLC

Phase 3

2 9

Vivarin

HHikma Pharmaceuticals LLC

Phase 3

1 10

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Chronic Coronary Syndrome

NCT06171061

Q4 2030

Post-ApprovalRecruiting

Heart Disease

NCT07110415

Clinical

Trials by Indication[1]

Chronic Coronary Syndrome2 trials

Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY）

Unknown status·—·Phase 4·NCT05978089·120 enrolled

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome

Recruiting·SShandong First Medical University·Phase 4·NCT06171061·1,200 enrolled

Heart Disease1 trial

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

Recruiting·SSPH Qingdao Growful Pharmacetical Co.,Ltd·Phase 4·NCT07110415·2,708 enrolled

Tolerance1 trial

Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI

Completed·SShenyang Northern Hospital·Phase 4·NCT03809273·681 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Yangxinshi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Yangxinshi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Yangxinshi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SPH Qingdao Growful Pharmacetical Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSPH Qingdao Growful Pharmacetical Co.,Ltd

Yangxinshi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2030

Trials by Indication[1]

Chronic Coronary Syndrome2 trials

Heart Disease1 trial

Tolerance1 trial

References

Drug Info

Quick Facts

Related News